Veterinary Tablets
Cestex (epsiprantel) tablets are indicated for the removal of tapeworms in the cat (Dipylidium caninum and Taenia taeniaeformis) and dog (Dipylidium caninum and Taenia pisiformis).
DESCRIPTION
Cestex tablets are film-coated and contain 12.5 mg, 25 mg, 50 mg or 100 mg of epsiprantel per tablet.
Epsiprantel is an anthelmintic that is active as a single dose against the common tapeworms of cats and dogs. Epsiprantel has a molecular weight of 326 and is chemically 2-(cyclohexyl-carbonyl)-4-oxo 1,2,3,4,6,7,8,12b-octahydropyrazino[2,1-a][2]benza-zepine. It is a stable white solid which is sparingly soluble in water. Its chemical structure is presented below.
INDICATIONS AND USAGE
Cestex tablets are indicated for the removal of the following:
Feline cestodes: Dipylidium caninum and Taenia taeniaeformis
Canine cestodes: Dipylidium caninum and Taenia pisiformis
WARNINGS
For use in cats and dogs only. Safety of use in pregnant or breeding animals has not been determined. Keep out of reach of children. Not for use in humans.
DOSAGE AND ADMINISTRATION
Cestex tablets should be administered orally.
The recommended dosage of epsiprantel is: cats, 1.25 mg/lb of body weight; dogs, 2.5 mg/lb of body weight. The following table may be used as a guide:
| Feline | |
| Body Weight | Dose |
| Seven weeks old up to 10 lb | 12.5 mg |
| 11–20 lb | 25.0 mg |
| Canine | |
| Body Weight | Dose |
| Seven weeks old up to 5 lb | 12.5 mg |
| 6–10 lb | 25.0 mg |
| 11–20 lb | 50.0 mg |
| 21–40 lb | 100.0 mg |
| 41–50 lb | 125.0 mg |
| 51–60 lb | 150.0 mg |
| 61–80 lb | 200.0 mg |
| 81–90 lb | 225.0 mg |
| 91–100 lb | 250.0 mg |
| 101+ lb | 2.5 mg/lb, rounding up to next whole tablet combination |
Fasting is not necessary or recommended.
Unless exposure to the infected intermediate hosts is controlled, reinfection is likely and retreatment may be required. In the case of D. caninum, an effective flea control program should be instituted.
SAFETY
Epsiprantel has been evaluated in cats at 5 times the recommended dose given once daily for 3 days with no adverse effects noted. In tolerance studies, epsiprantel produced minimal clinical signs in cats given 40 times the recommended dose once daily for 4 days.
Epsiprantel has been evaluated in 14-day repeat dose studies in dogs at 500 mg/kg (90 times recommended dosage) with no significant adverse results. No side effects were observed during the clinical field studies.
Epsiprantel is not a cholinesterase inhibitor. During the course of clinical field studies, Cestex was administered concurrently with diethylcarbamazine citrate (dogs only), anti-inflammatory agents, insecticides, and nematocides with no drug incompatibilities noted.
STORAGE
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions between 15°-30°C (59°-86°F).
HOW SUPPLIED
Cestex tablets are film-coated and contain 12.5 mg, 25 mg, 50 mg or 100 mg of epsiprantel per tablet. Cestex is supplied as described below:
| Weight (lbs) | Number | ||
|---|---|---|---|
| Concentration | Cat | Dog | Tablets/Bottle |
| 12.5 mg | 10 | 5 | 50, 100 |
| 25.0 mg | 20 | 10 | 50, 100 |
| 50.0 mg | – – | 20 | 25, 50 |
| 100.0 mg | – – | 40 | 25, 50 |
Approved by FDA under NADA # 140-893
zoetis
Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
40027642
Revised: May 2019
